How Genomic Data Improves Drug Development Timelines and Success

Genomic data is rapidly reshaping drug development, but not all data delivers the same value. For biopharma teams, the ability to accurately identify patients, understand disease burden, and make confident development decisions depends on integrating clinically validated genomic insights with real-world data.

This webinar will explore how integrating clinical-grade genomic data with longitudinal insights can fuel drug discovery, accelerate precise clinical trials, advance HEOR research, and generate evidence to deliver value across the drug development lifecycle.

Many current approaches rely heavily on claims data, which often lack the specificity needed to accurately define genetically driven diseases. This can lead to misidentified patient populations and an incomplete understanding of disease burden. In contrast, clinically derived genomic data paired with longitudinal insights provides a precise, end-to-end view of patient populations and links molecular diagnosis to real-world outcomes.

The featured speakers will demonstrate how this integrated approach can support more confident development decisions and will introduce Infinity™, one of the world’s largest clinically derived genomic datasets, spanning over 2.5M genetic tests, 1M exomes and genomes, and more than 8M phenotypic datapoints. The dataset now includes claims data to enable more accurate and actionable insights. Using multimodal AI, Infinity is designed to support biomarker discovery, genetic target validation, and natural history modeling.

Through a structured, three-pillar framework, the webinar will examine payer mix, highlighting differences in coverage, access, and patient demographics. It will also review healthcare resource utilization, including hospitalizations and emergency department visits, and analyze the cost of care to more precisely illustrate the financial impact of rare and genetic diseases.

Register for this webinar to learn how genomic data can improve patient identification, strengthen evidence generation, and support more confident drug development decisions.

Speakers

Lisa Gurry, Chief Business Officer, GeneDx

Lisa Gurry is the Chief Business Officer at GeneDx, where she leads strategic growth across biopharma, health systems and partners to advance precision medicine. She oversees strategic partnerships, biopharma partnerships, data product strategy, marketing and communications, helping unlock the full potential of GeneDx Infinity, one of the world’s largest genomic datasets.

Lisa brings deep expertise at the intersection of healthcare, technology and data, with a strong track record of scaling innovative businesses. She co-founded Truveta, where she held roles including Chief Growth Officer, Chief Marketing Officer and Chief Operating Officer. Earlier in her career, she spent more than 20 years at Microsoft.

Message Presenter

Colton Frazer, Senior Health Economics & Outcomes Research Scientist, GeneDx

Colton Frazer is a Senior Health Economics & Outcomes Research (HEOR) Scientist at GeneDx, where he evaluates the clinical and economic value of genetic testing to inform biopharma decision-making. He brings deep expertise in real-world evidence, outcomes research and value demonstration, with a focus on rare and complex diseases.

Prior to GeneDx, Colton was Senior Manager of HEOR at Vertex Pharmaceuticals, where he led evidence-generation strategies for early-stage pipeline products. He completed an HEOR fellowship at Agios Pharmaceuticals, applying outcomes research to novel therapeutics, particularly in rare diseases. He holds a PharmD and MBA, combining scientific and business expertise to translate data into strategic insight.

In addition to his industry work, Colton has served as Adjunct Faculty at the Saint Louis College of Pharmacy and the Massachusetts College of Pharmacy and Health Sciences, mentoring future healthcare professionals and contributing to academic research.

Message Presenter